PHILADELPHIA, PA, March 2, 2021--The »Æ¹ÏµÎµÎapp (ACP) supports the interim recommendation of the Advisory Committee on Immunization Practices (ACIP) to the Centers for Disease Control and Prevention (CDC) for the use of the COVID-19 vaccine from Johnson & Johnson through its wholly-owned subsidiary, Janssen, in persons 18 and older in the U.S. under the Food and Drug Administration’s Emergency Use Authorization.
WASHINGTON, Feb. 10 — The »Æ¹ÏµÎµÎapp (ACP) signaled its strong support for provisions in the COVID relief legislation prepared by two congressional committees to increase access to health care services and health insurance coverage and combat the COVID-19 pandemic.
PHILADELPHIA, Feb. 9, 2021 – In updated , the »Æ¹ÏµÎµÎapp (ACP) addresses emerging evidence regarding the effectiveness of remdesivir in hospitalized patients with COVID-19 and whether benefits and harms vary by symptom duration, disease severity, and treatment duration. The paper, developed by the Scientific Medical Policy Committee of the ACP, Should Remdesivir Be Used for the Treatment of Patients with COVID-19?
Statement attributable to:
Jacqueline W. Fincher, MD, MACP,
President, »Æ¹ÏµÎµÎapp
